Table I.
Baseline characteristics for WM and IgM MGUS patients whose samples were evaluated for CXCR4 mutations by AS-PCR and Sanger sequencing.
| Untreated WM | Previously Treated WM | IgM MGUS | |
|---|---|---|---|
| N | 102 | 62 | 12 |
| Age (years) | 62 (33–88) | 63 (44–86) | 69 (56–82) |
| Gender (Male/Female) | 58/44 | 48/15 | 6/6 |
| Serum IgM (g/l) | 26·70 (2·70–86·30) | 36·10 (7·35–83·90) | 3·97 (1·42–16·40) |
| Haemoglobin (g/l) | 117 (48–155) | 105 (82–138) | 134 (119–163) |
| Serum β2-microglobulin (mg/l) | 2·9 (1·0–9·5) | 3·9 (1·3–14·2) | 1·9 (1·7–3·4) |
| Adenopathy (≥ 1·5 cm) | 34 (33·3%) | 37 (58·7%) | 0 (0%) |
| Splenomegaly (≥15 cm) | 15 (14·7%) | 7 (11·1%) | 0 (0%) |
| Bone marrow involvement (%) by IHC | 40 (5–95) | 60 (3–95) | 0 (0%) (0–0) |
| MYD88L265P positive | 97 (95·1%) | 55 (89%) | 6 (50%) |
WM, Waldenström Macroglobulinaemia; IgM, immunoglobulin M; MGUS, monoclonal gammopathy of unknown significance; AS-PCR, allele-specific polymerase chain reaction; IHC, immunohistochemistry.
Values are shown as median (range) unless otherwise indicated.